We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Colleague Insights
Grand Rounds
Conferences
Video Expert Opinion
Living Resources
Sign in
Join now
story of the week
Published in Cardiometabolic Disease and Diabetes and
2 other channels

Journal Scan / Research · February 01, 2021

Empagliflozin Beneficial for Nondiabetic Patients With HFrEF

JACC: Journal of the American College of Cardiology

 

Save Recommend
Share

Additional Info

JACC: Journal of the American College of Cardiology
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
J Am Coll Cardiol 2021 Jan 26;77(3)243-255, CG Santos-Gallego, AP Vargas-Delgado, JA Requena-Ibanez, A Garcia-Ropero, D Mancini, S Pinney, F Macaluso, S Sartori, M Roque, F Sabatel-Perez, A Rodriguez-Cordero, MU Zafar, I Fergus, F Atallah-Lajam, JP Contreras, C Varley, PR Moreno, VM Abascal, A Lala, R Tamler, J Sanz, V Fuster, JJ Badimon, EMPA-TROPISM (ATRU-4) Investigators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated